InVivo Therapeutics appoints Dr. Robert Rosenthal to board of directors

Robert Rosenthal, PhD, was appointed to the board of directors at InVivo Therapeutics on Nov. 8.

Advertisement

Three things to know:

1. InVivo is a clinical-stage biomaterials and biotechnology company focusing on the treatment of spinal cord injuries.

2. Dr. Rosenthal serves as chairman of the board of Taconic Biosciences and director at Safeguard Scientifics and Galvanic Applied Sciences, among other leadership positions.

3. He has more than 25 years of experience in leadership positions and plans to advance InVivo’s “clinical pathway to ultimately address an … unmet need for spinal cord injury patients.”

More articles on devices:
2 hospitals losing neurosurgery residency programs
Rothman, Carrum Health partner to expand healthcare benefits into tri-state area
Nexxt Spine to expand headquarters — 4 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • Stryker CEO Kevin Lobo’s total compensation was $21.4 million in 2025, according to a recent Securities and Exchange Commission proxy filing.…

  • John DeFord, PhD, is stepping down from Globus Medical’s board of directors, according to a March 23 news release. His…

Advertisement

Comments are closed.